Efficacy and Safety of Concizumab prophylaxis in patients with haemophilia A or B with inhibitors - explorer7

ovo Nordisk A/S0 个研究点目标入组 136 人开始时间: 2019年10月9日最近更新: 2021年3月30日

适应症

试验速览

暂无简介。

•- Informed consent obtained before any trial-related activities. Trial-related activities are any procedures that are carried out as part of the trial, including activities to determine suitability for the trial
•- Male aged 12 or older years at the time of signing informed consent
•- Congenital Haemophilia A or B of any severity with documented history of inhibitor (0.6 BU or more)
•- Patient has been prescribed, or in need of, treatment with bypassing agents in the last 24 weeks prior to screening (for patients not previously enrolled in NN7415-4310 (explorer 4))
•Are the trial subjects under 18? yes
•Number of subjects for this age range: 15
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 96
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 10

•- Known or suspected hypersensitivity to any constituent of the trial product or related
•- Known inherited or acquired coagulation disorder other than congenital haemophilia
•- Ongoing or planned Immune Tolerance Induction treatment
•- History of thromboembolic disease (includes arterial and venous thrombosis including myocardial infarction, pulmonary embolism, cerebral infarction/thrombosis, deep vein thrombosis, other clinically significant thromboembolic events and peripheral artery occlusion). Current clinical signs of, or treatment for thromboembolic disease. Patients who in the judgement of the investigator are considered at high risk of thromboembolic events (thromboembolic risk factors could include, but are not limited to, hypercholesterolemia, diabetes mellitus, hypertension, obesity, smoking, family history of thromboembolic events, arteriosclerosis, other conditions associated with increased risk of thromboembolic events.)

发起方